Lactobacillus paracasei WIS43 alleviates DSS-induced colitis by modulating gut microbiota and suppressing inflammation
Frontiers in Microbiology · 29.01.2026 · 16
DOI: 10.3389/fmicb.2025.1721585 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Microbiology, online erschienen am 29.01.2026. Verfasst von Yu Fu und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin, China. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Ulcerative colitis (UC) is a chronic inflammatory disorder of the colon with rising incidence and limited therapeutic options. Probiotics are increasingly recognized as potential interventions, but strain-specific differences remain insufficiently defined.
Methods
We conducted a meta-analysis of publicly available microbiome datasets to characterize disease-associated dysbiosis, focusing on the genus Lactobacillus . We then evaluated Lactobacillus paracasei WIS43, a novel strain isolated from the breast milk of a healthy volunteer, in a dextran sulfate sodium (DSS)-induced murine colitis model, using mesalazine and the commercial strain Lactobacillus paracasei LPC-37 as comparators. Disease severity, histopathology, inflammatory cytokines, and gut microbiota composition were systematically assessed.
Results
Meta-analysis confirmed a significant depletion of Lactobacillus in UC patients. In vivo , WIS43 treatment reduced body weight loss, disease activity index scores, and colon shortening. Histological analysis revealed preserved epithelial integrity and reduced inflammatory infiltration. WIS43 significantly decreased serum and colonic TNF- α , IL-6, and IL-1β levels, demonstrating stronger anti-inflammatory activity than LPC-37 and comparable efficacy to mesalazine. 16S rRNA sequencing further showed that WIS43 restored beneficial taxa, including Lactobacillus johnsonii and Lactobacillus taiwanensis , while reducing potentially pathogenic bacteria.
Conclusion
These findings identify WIS43 as a promising probiotic candidate for the prevention and treatment of UC, supporting its therapeutic potential through coordinated modulation of host immunity and gut microbiota.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
- PKUMed-Wisbiom Joint Laboratory for Human Microbiome Research, Institute of Advanced Clinical Medicine, Peking University, Beijing, China.
- Department of Pharmacy, Tianjin Jizhou District People's Hospital, Tianjin, China.
- Tianjin Key Laboratory of Therapeutic Substance of Traditional Chinese Medicine, Tianjin, China.
Zitieren
APA
Fu, Y., Chen, S., Cui, L., Cao, Y., Dong, Y., Duan, Y., & Wu, C. (2026). Lactobacillus paracasei WIS43 alleviates DSS-induced colitis by modulating gut microbiota and suppressing inflammation. Frontiers in Microbiology, 16. https://doi.org/10.3389/fmicb.2025.1721585
Vancouver
Fu Y, Chen S, Cui L, Cao Y, Dong Y, Duan Y, et al. Lactobacillus paracasei WIS43 alleviates DSS-induced colitis by modulating gut microbiota and suppressing inflammation. Frontiers in Microbiology. 2026;16. doi:10.3389/fmicb.2025.1721585
BibTeX
@article{Fu2026,
author = {Fu, Yu and Chen, Shuxia and Cui, Lei and Cao, Ying and Dong, Yanan and Duan, Yunfeng and Wu, Chongming},
title = {Lactobacillus paracasei WIS43 alleviates DSS-induced colitis by modulating gut microbiota and suppressing inflammation},
journal = {Frontiers in Microbiology},
year = {2026},
volume = {16},
doi = {10.3389/fmicb.2025.1721585}
}
EUVIMED